PLUS1
29.92
0.00 (0.00%)
0.00 (0.00%)
Upgrade to Real-Time
Afterhours
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Castle Biosciences Inc | CSTL | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 3.10 | 11.56% | 29.92 | 25.92 | 30.23 | 26.17 | 26.82 | 16:30:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 15.40 | 50.00 | 34.60 | 69.2% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,465 | 167,514 | $ 27.38 | $ 4,587,054 | 120,527 | 15.26 - 39.77 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:01:03 | formt | 446 | $ 29.92 | USD |
Castle Biosciences Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 510.86M | 17.07M | $ 669.00k | -0.62 | 80.10 | 15.11M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 4.00 | 11.50% |
Castle Biosciences News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/25/2020 | 07:00 | Business Wire | Castle Biosciences to Release Fourth Quarter & Full Year.. |
| 2/21/2020 | 17:51 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/21/2020 | 17:23 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/18/2020 | 17:30 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/18/2020 | 17:23 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/12/2020 | 16:55 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) |
| 2/12/2020 | 16:47 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CSTL Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 31.76 | 33.50 | 25.92 | 29.74 | 109,169 | -1.84 | -5.79% |
| 1 Month | 29.61 | 33.50 | 25.92 | 30.74 | 124,424 | 0.31 | 1.05% |
| 3 Months | 29.34 | 39.77 | 24.81 | 30.99 | 117,338 | 0.58 | 1.98% |
| 6 Months | 24.00 | 39.77 | 15.26 | 26.25 | 121,540 | 5.92 | 24.67% |
| 1 Year | 20.00 | 39.77 | 15.26 | 25.15 | 136,403 | 9.92 | 49.6% |
| 3 Years | 20.00 | 39.77 | 15.26 | 25.15 | 136,403 | 9.92 | 49.6% |
| 5 Years | 20.00 | 39.77 | 15.26 | 25.15 | 136,403 | 9.92 | 49.6% |
Castle Biosciences Description
| Castle Biosciences Inc is a United States-based company engaged in developing and commercializing diagnosis and prognostic tests for dermatologic cancers. Its non-invasive products utilize algorithms to provide an assessment of a patient's specific risk of metastasis or recurrence of their cancer. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others. |
